ArticleCancers2020
Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.8field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 63 citations in OpenAlex.
- Evolving techniques to optimize ERCP-based sampling and evaluation of malignant biliary strictures.Gastroenterology report · 2026Review
- Cholangiocarcinoma 2026: status quo, unmet needs and priorities.Nature reviews. Gastroenterology & hepatology · 2026Review
- A guide for establishing patient-derived organoids from bile samples obtained during endoscopic procedures and performing gene expression knockdown.Frontiers in cell and developmental biology · 2026Article
- Ultra-low-pass whole-genome sequencing of bile cfDNA in patients with biliary strictures.eGastroenterology · 2026Article
- Use of Nuclear Magnetic Resonance (NMR) to Study Cancer Metabolism.Advances in experimental medicine and biology · 2026Review
- GBCapsNet: A calibrated capsule network for automated gallbladder disease diagnosis via ultrasound imaging.PloS one · 2026Article
- Integrating multi-omics in bile for biomarker discovery in cholangiocarcinoma.Hepatology communications · 2025Article
- Advancements in Radiomics-Based AI for Pancreatic Ductal Adenocarcinoma.Bioengineering (Basel, Switzerland) · 2025Review
- Associations between prediagnostic plasma metabolites and biliary tract cancer risk in the prospective UK Biobank cohort.American journal of epidemiology · 2025Article
- Emerging Biomarker Potential of Extracellular Vesicle-Enclosed MicroRNAs for Liver Fibrosis Detection.Cells · 2025Review
- Advancements in the diagnosis of biliopancreatic diseases: A comparative review and study on future insights.World journal of gastrointestinal endoscopy · 2025Review
- Biomarkers and Management of Cholangiocarcinoma: Unveiling New Horizons for Precision Therapy.Cancers · 2025Review
- Mutational Analysis of Bile Cell-Free DNA in Primary Sclerosing Cholangitis: A Pilot Study.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic Significance.The American journal of pathology · 2025Review
- Bile-Derived cfDNA of Syncytin-1 and SLC7A11 as a Potential Molecular Marker for Early Diagnosis of Cholangiocarcinoma.Journal of gastrointestinal cancer · 2025Article
- Significantly higher incidence of circulating fatty objects in portal blood samples compared to peripheral blood samples in patients with pancreatic ductal adenocarcinoma.Frontiers in oncology · 2025Article
- From multi-omics to predictive biomarker: AI in tumor microenvironment.Frontiers in immunology · 2024Review
- Application of AI on cholangiocarcinoma.Frontiers in oncology · 2024Review
- Article
- Promising Highly Targeted Therapies for Cholangiocarcinoma: A Review and Future Perspectives.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 8 institutions in 1 country.
Jesús M UrmanDepartment of Gastroenterology and Hepatology, Navarra University Hospital Complex, 31008 Pamplona, Spain.
José M HerranzNational Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Carlos III Health Institute, 28029 Madrid, Spain.ORCID 0000-0002-6031-535X
Iker UriarteNational Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Carlos III Health Institute, 28029 Madrid, Spain.ORCID 0000-0001-5237-7799
María RullánDepartment of Gastroenterology and Hepatology, Navarra University Hospital Complex, 31008 Pamplona, Spain.
Daniel OyónDepartment of Gastroenterology and Hepatology, Navarra University Hospital Complex, 31008 Pamplona, Spain.
Belén GonzálezDepartment of Gastroenterology and Hepatology, Navarra University Hospital Complex, 31008 Pamplona, Spain.
Ignacio Fernandez-UriénDepartment of Gastroenterology and Hepatology, Navarra University Hospital Complex, 31008 Pamplona, Spain.
Juan CarrascosaDepartment of Gastroenterology and Hepatology, Navarra University Hospital Complex, 31008 Pamplona, Spain.
Federico BoladoDepartment of Gastroenterology and Hepatology, Navarra University Hospital Complex, 31008 Pamplona, Spain.ORCID 0000-0003-1522-2434
Lucía ZabalzaDepartment of Gastroenterology and Hepatology, Navarra University Hospital Complex, 31008 Pamplona, Spain.
María ArechederraIdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.ORCID 0000-0002-4830-1924
Gloria Alvarez-SolaNational Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Carlos III Health Institute, 28029 Madrid, Spain.
Leticia ColynProgram of Hepatology, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.
María U LatasaProgram of Hepatology, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.
Leonor Puchades-CarrascoDrug Discovery Unit, Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain.ORCID 0000-0003-0340-7458
Antonio Pineda-LucenaDrug Discovery Unit, Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain.
María J IraburuDepartment of Biochemistry and Genetics, School of Sciences; University of Navarra, 31008 Pamplona, Spain.
Marta Iruarrizaga-LejarretaOWL Metabolomics, Bizkaia Technology Park, 48160 Derio, Spain.ORCID 0000-0002-3836-0162
Cristina AlonsoOWL Metabolomics, Bizkaia Technology Park, 48160 Derio, Spain.ORCID 0000-0002-2019-678X
Bruno SangroIdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.
Ana PurroyIdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.
Isabel GilIdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.
Lorena CarmonaProteomics Unit, Centro Nacional de Biotecnología (CNB) Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, Spain.
Francisco Javier CuberoDepartment of Immunology, Ophtalmology & Ear, Nose and Throat (ENT), Complutense University School of Medicine and 12 de Octubre Health Research Institute (Imas12), 28040 Madrid, Spain.ORCID 0000-0003-1499-650X
María L Martínez-ChantarNational Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Carlos III Health Institute, 28029 Madrid, Spain.ORCID 0000-0002-6446-9911
Jesús M BanalesNational Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Carlos III Health Institute, 28029 Madrid, Spain.
Marta R RomeroNational Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Carlos III Health Institute, 28029 Madrid, Spain.ORCID 0000-0001-6729-0215
Rocio I R MaciasNational Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Carlos III Health Institute, 28029 Madrid, Spain.ORCID 0000-0002-4748-0326
Maria J MonteNational Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Carlos III Health Institute, 28029 Madrid, Spain.ORCID 0000-0003-1844-7428
Jose J G MarínNational Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Carlos III Health Institute, 28029 Madrid, Spain.ORCID 0000-0003-1186-6849
Juan J VilaDepartment of Gastroenterology and Hepatology, Navarra University Hospital Complex, 31008 Pamplona, Spain.
Fernando J CorralesNational Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Carlos III Health Institute, 28029 Madrid, Spain.ORCID 0000-0002-0231-5159
Carmen BerasainIdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.ORCID 0000-0001-7075-2476
Maite G Fernández-BarrenaIdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.ORCID 0000-0003-0375-6236
Matías A AvilaIdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.ORCID 0000-0001-6570-3557
Instituto de Salud Carlos III · ESUniversidad de Navarra · ESNavarre Institute of Health Research · ESUniversidad de Salamanca · ESConsejo Superior de Investigaciones Científicas · ESEuskadiko Parke Teknologikoa · ESInstituto de Investigación Sanitaria La Fe · ESIkerbasque · ES
Funding
AMMF, The Cholangiocarcinoma Charity 2018/117BIOEF, EiTB Maratoia. BIO15/CA/016/BD and BIO15/CA/011Department of Health of the Basque Country 2017111010EU, Horizon 2020 (H2020) ESCALON project H2020-SC1-BHC-2018-2020Fundación BBVA Ayudas a Equipos de Investigación Científica Umbrella 2018Fundación Científica Asociación Española Contra el Cáncer Tumores raros 2017Gobierno de Navarra, Salud 58/17Instituto de Salud Carlos III PI16/01126, PI19/00819, PI15/01132, PI18/01075 and Miguel Servet Program CON14/00129.La Caixa Foundation Hepacare and LCF/PR/HP17/52190004 grants.Mineco-Feder. SAF2017-87301-RPSC Partners US, PSC Supports UK 06119JBRamón y Cajal Program RYC-2014-15242 and RYC2018-024475-1Severo Ochoa Excellence Accreditation SEV-2016-0644
Abstract
Cholangiocarcinoma (CCA) and pancreatic adenocarcinoma (PDAC) may lead to the development of extrahepatic obstructive cholestasis. However, biliary stenoses can also be caused by benign conditions, and the identification of their etiology still remains a clinical challenge. We performed metabolomic and proteomic analyses of bile from patients with benign (
Indexed as
cholangiocarcinomahuman bilelipidomicsmachine-learningpancreatic adenocarcinomaproteomics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.